Tolvaptan is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic ...

With this launch, Lupin's FY26 revenue opportunity is estimated at $150–200 million. gTolvaptan could contribute over 25% to ...

to market a generic equivalent of Descovy® Tablets, 200 mg/25 mg of Gilead Sciences, Inc," Lupin said in an exchange filing. The approval allows Lupin to market a generic version of Descovy ...

Lupin Ltd. and Zydus Lifesciences Ltd. shares fell sharply after a US court upheld Astellas Pharma’s patent on Myrbetriq, ...

The ruling blocks Lupin and Zydus Life from selling their generic version of Mirabegron, the bioequivalent of Astellas' ...

AMLODIPINE ATORVASTATIN MYLAN film-coated tablet 10 mg+10 mg Mylan Pharms Inc. AMLODIPINE ATORVASTATIN MYLAN film-coated tablet 10 mg+2.5 mg Mylan Pharms Inc ...

AMLODIPINE ATORVASTATIN MYLAN film-coated tablet 10 mg+10 mg Mylan Pharms Inc. AMLODIPINE ATORVASTATIN MYLAN film-coated tablet 10 mg+2.5 mg Mylan Pharms Inc ...

Shares of Indian pharmaceutical majors Lupin Ltd ... were among the first to launch 25 mg versions of the drug in the US and had plans to roll out the 50 mg dosage soon. Analysts noted that ...

Technical analysis identifies select stocks that may gain momentum even in volatile markets. Here are the technical calls for today.

Global pharma major Lupin Ltd today announced that it has received the Establishment Inspection Report from the United States Food and Drug Administration, for drug-medical device combination products ...

Naples-based Lupin Pharmaceuticals Inc is recalling 2,724 bottles of clomiPRAMINE hydrochloride Capsules USP, 25 mg, due to "Failed Impurities/Degradation Specifications", USFDA said. The company ...

Lupin, operating in the Pharmaceuticals sector and classified as a Largecap on the BSE, currently has its share price at ₹1934.5. The stock has experienced fluctuations today, with a low of ...